Solid Biosciences Inc SLDB:NASDAQ

Last Price$0.80NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22

Today's Change+0.02(2.73%)
Bid (Size)$0.80 (22)
Ask (Size)$0.82 (10)
Day Low / High$0.73 - 0.82
Volume604.4 K
  • Latest Stories
  • Commentary and Analysis
--Chardan Research Adjusts Price Target on Solid Biosciences to $6 From $7, Reiterates Buy Rating
3:52AM ET 8/12/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Top Premarket Decliners
7:58AM ET 7/29/2022 MT Newswires

Avaya (AVYA) shares slumped 23% after the company said it now expects fiscal Q3 revenue to range from $575 million to $580 million, lower than its...

Piper Sandler Adjusts Price Target on Solid Biosciences to $2 From $5, Maintains Neutral Rating
8:01AM ET 5/19/2022 MT Newswires

Solid Biosciences (SLDB) has an average rating of outperform and price targets ranging from $2 to $12, according to analysts polled by Capital IQ. (MT...

--Piper Sandler Adjusts Solid Biosciences' Price Target to $5 From $6, Maintains Neutral Rating
8:52AM ET 4/28/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--SVB Leerink Adjusts Price Target on Solid Biosciences to $12 From $5, Keeps Outperform Rating
8:52AM ET 4/28/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Chardan Research Adjusts Price Target on Solid Biosciences to $7 From $17 on Duchenne Muscular Dystrophy Market Assumptions, Reiterates Buy Rating
5:32AM ET 4/28/2022 MT Newswires

Solid Biosciences (SLDB) has an average rating of outperform and price targets ranging from $2 to $12, according to analysts polled by Capital IQ. (MT...

Solid Biosciences, Forge Biologics Team Up to Develop Gene Therapy for Muscular Dystrophy
10:34AM ET 10/04/2021 MT Newswires

Solid Biosciences (SLDB) said Monday it is working with Forge Biologics for the development and manufacturing of its SGT-003, which is intended for the...

Solid Biosciences Reports Additional Pulmonary Function Data From Phase 1/2 Clinical Trial of Duchenne Therapy Candidate
8:00AM ET 9/29/2021 MT Newswires

Solid Biosciences (SLDB) reported additional positive pulmonary function data from the first six patients in a phase 1/2 clinical trial of SGT-001, a gene...

Chardan Adjusts Price Target on Solid Biosciences to $17 From $20, Maintains Buy Rating
11:17AM ET 9/24/2021 MT Newswires

Solid Biosciences (SLDB) has an average outperform rating and a price target range of $2 to $17, according to analysts polled by Capital IQ. (MT Newswires...

Solid Biosciences to Unveil 'Positive' Data for Duchenne Muscular Dystrophy Treatment -- Shares Jump in Pre-Market
6:30AM ET 9/23/2021 MT Newswires

Solid Biosciences (SLDB) said Thursday it will report "positive" data from a phase I/II trial of its drug SGT-001 to treat Duchenne muscular dystrophy. ...